Repligen Co. (NASDAQ:RGEN) Director Margaret Pax Purchases 250 Shares

Repligen Co. (NASDAQ:RGEN) Director Margaret Pax bought 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the transaction, the director now owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Repligen Trading Down 5.5 %

Repligen stock traded down $8.47 during trading on Tuesday, hitting $144.34. The company’s stock had a trading volume of 1,156,151 shares, compared to its average volume of 646,141. The stock has a market capitalization of $8.09 billion, a price-to-earnings ratio of -283.02, a P/E/G ratio of 4.54 and a beta of 0.95. The stock’s fifty day moving average is $157.16 and its 200 day moving average is $148.53. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $200.23. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. As a group, equities research analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Institutional Investors Weigh In On Repligen

Institutional investors have recently added to or reduced their stakes in the company. Signaturefd LLC grew its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. purchased a new stake in shares of Repligen in the fourth quarter worth about $29,000. Raiffeisen Bank International AG purchased a new stake in shares of Repligen in the fourth quarter worth about $29,000. Resources Management Corp CT ADV purchased a new stake in shares of Repligen in the third quarter worth about $37,000. Finally, Quarry LP boosted its position in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock worth $40,000 after buying an additional 239 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Evercore ISI initiated coverage on Repligen in a research note on Tuesday. They issued an “in-line” rating and a $155.00 target price on the stock. Finally, Royal Bank of Canada lifted their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday, February 21st. One analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.